These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Autologous, allogeneic tumor cells or genetically engineered cells as cancer vaccine against melanoma. Schadendorf D; Paschen A; Sun Y Immunol Lett; 2000 Sep; 74(1):67-74. PubMed ID: 10996630 [TBL] [Abstract][Full Text] [Related]
5. Melanoma-associated tumor antigens and their clinical relevance to immunotherapy. Gattoni-Celli S; Cole DJ Semin Oncol; 1996 Dec; 23(6):754-8. PubMed ID: 8970598 [TBL] [Abstract][Full Text] [Related]
6. Application of Alphaviral Vectors for Immunomodulation in Cancer Therapy. Zajakina A; Spunde K; Lundstrom K Curr Pharm Des; 2017; 23(32):4906-4932. PubMed ID: 28641531 [TBL] [Abstract][Full Text] [Related]
7. Evolving role of tumor antigens for future melanoma therapies. Andrews MC; Woods K; Cebon J; Behren A Future Oncol; 2014 Jun; 10(8):1457-68. PubMed ID: 25052755 [TBL] [Abstract][Full Text] [Related]
8. Current immunotherapeutic strategies in malignant melanoma. Agostino NM; Ali A; Nair SG; Mosca PJ Surg Oncol Clin N Am; 2007 Oct; 16(4):945-73, xi. PubMed ID: 18022553 [TBL] [Abstract][Full Text] [Related]
9. Novel recombinant alphaviral and adenoviral vectors for cancer immunotherapy. Osada T; Morse MA; Hobeika A; Lyerly HK Semin Oncol; 2012 Jun; 39(3):305-10. PubMed ID: 22595053 [TBL] [Abstract][Full Text] [Related]
10. An alphavirus-based therapeutic cancer vaccine: from design to clinical trial. Singh A; Koutsoumpli G; van de Wall S; Daemen T Cancer Immunol Immunother; 2019 May; 68(5):849-859. PubMed ID: 30465060 [TBL] [Abstract][Full Text] [Related]